Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Enzo Biochem, Inc., an integrated diagnostics, clinical lab, and life sciences company, researches, develops, manufactures, and markets diagnostic and research products based on genetic engineering, biotechnology, and molecular biology. It operates through three segments: Products, Clinical Services, and Therapeutics. The Products segment develops, manufactures, and markets products and tools to clinical research, drug development, and bioscience research customers. It offers proteins, antibodies, peptides, small molecules, labeling probes, dyes, and kits, which provide life science researchers tools for target identification/validation, content analysis, gene expression analysis, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment provides its products to scientific experts in the fields of cancer, cardiovascular disease, neurological disorders, diabetes and obesity, endocrine disorders, infectious and autoimmune disease, hepatotoxicity, and renal injury. The Clinical Services segment provides routine and esoteric clinical laboratory tests or procedures used in general patient care by physicians to establish or support a diagnosis, monitor treatment or medication, or search for an otherwise undiagnosed condition. It operates a full-service clinical laboratory in Farmingdale, New York; a network of 34 patient service centers in New Yo...
Website: enzo.com



Growth: Bad revenue growth rate -38.5%, there is slowdown compared to average historical growth rates 4.7%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -47.1%. On average the margin is decreasing steadily. Gross margin is low, +10.2%.

Cash Flow Generation: Dividend yield for the last twelve months 31.9%. Free cash flow yield -196.2% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 20.3% higher than minimum and 88.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -1.2x by EV / Sales multiple

Key Financials (Download financials)

Ticker: ENZ
Share price, USD:  (0.0%)0.3138
year average price 0.3669  


year start price 0.7063 2025-01-08

max close price 0.7063 2025-01-08

min close price 0.2608 2025-04-10

current price 0.3138 2026-01-07
Common stocks: 48 720 503

Dividend Yield:  31.9%
EV / Sales: 0.5x
Margin (EBITDA LTM / Revenue): -47.1%
Fundamental value created in LTM:
Market Cap ($m): 15
Net Debt ($m): 19
EV (Enterprise Value): 34
Price to Book: 0.4x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-04-22globenewswire.com

Enzo Biochem, Inc. Announces Review of Strategic Alternatives after Receiving Multiple Inquiries Regarding a Potential Transaction

2025-03-28globenewswire.com

Enzo Biochem Announces Notification to New York Stock Exchange of Intention to Voluntarily Delist Common Stock and Transfer Trading of Shares to OTCQX

2025-01-14globenewswire.com

Enzo Biochem Receives Notice of Non-Compliance with New York Stock Exchange Listing Rules

2024-12-19zacks.com

ENZ Stock Falls Post Q1 Earnings Amid Revenue and Demand Challenges

2024-12-16globenewswire.com

Enzo Biochem Reports First Quarter Fiscal Year 2025 Results and Provides a Company Update

2024-10-30zacks.com

ENZ Stock Up Following FY24 Earnings Uptick, Gross Margin Expands

2024-07-17seekingalpha.com

Enzo Biochem: Is This Time Finally Different?

2024-06-20zacks.com

Zacks Initiates Coverage of Enzo Biochem With Neutral Recommendation

2024-06-13globenewswire.com

Enzo Biochem Reports Third Quarter Fiscal 2024 Results and Provides Business Update

2023-10-26Seeking Alpha

Enzo Biochem: Cleaned Up And Cash-Rich But Unloved
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q1 2024 q4 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-04-30 2025-01-31 2024-07-31 2024-04-30 2024-01-31 2023-10-31 2023-07-31 2023-04-30 2023-01-31 2022-10-31
symbol ENZ ENZ ENZ ENZ ENZ ENZ ENZ ENZ ENZ ENZ
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 316 253 316 253 316 253 316 253 316 253 316 253 316 253 316 253 316 253 316 253
fillingDate 2025-06-16 2025-03-17 2024-10-29 2024-06-13 2024-03-13 2023-12-15 2023-11-03 2023-06-14 2023-03-20 2022-12-12
acceptedDate 2025-06-16 17:08:51 2025-03-17 16:15:19 2024-10-29 17:04:55 2024-06-13 16:15:33 2024-03-13 16:25:22 2023-12-15 16:15:29 2023-11-03 17:07:13 2023-06-14 17:14:22 2023-03-20 17:17:09 2022-12-12 17:02:46
calendarYear 2025 2025 2024 2024 2024 2024 2023 2023 2023 2023
period Q3 Q2 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
revenue 6M 7M 8M 8M 9M 8M -20M 16M 16M 18M
costOfRevenue 4M 4M 4M 4M 4M 4M 5M 14M 15M 15M
grossProfit 2M 4M 3M 4M 4M 3M -25M 2M 1M 4M
grossProfitRatio 0.388 0.516 0.428 0.465 0.494 0.443 1.258 0.102 0.077 0.197
researchAndDevelopmentExpenses 504 000 479 000 607 000 605 000 580 000 849 000 502 000 975 000 1M 996 000
generalAndAdministrativeExpenses 5M 5M 8M 4M 5M 7M 23M 0 12M 11M
sellingAndMarketingExpenses 0 -350 000 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 5M 5M 8M 4M 5M 7M -8M 12M 12M 11M
otherExpenses 0 350 000 -3M -290 000 -264 000 158 000 102 000 148 000 125 000 0
operatingExpenses 6M 5M 6M 5M 6M 8M -8M 13M 13M 12M
costAndExpenses 10M 9M 10M 9M 10M 12M -32M 27M 28M 27M
interestIncome 384 000 462 000 943 000 726 000 893 000 977 000 -62 000 0 62 000 0
interestExpense 0 0 197 000 0 0 0 -8M 8M 62 000 70 000
depreciationAndAmortization 318 000 318 000 398 000 337 000 267 000 270 000 606 000 5M 149 000 3M
ebitda -3M -1M -2M -1M -1M -2M 13M -7M -12M -6M
ebitdaratio -0.48 -0.175 -0.272 -0.126 -0.135 -0.221 -0.644 -0.42 -0.724 -0.338
operatingIncome -3M -2M -3M -1M -1M -5M 14M -11M -12M -9M
operatingIncomeRatio -0.529 -0.218 -0.354 -0.168 -0.166 -0.702 -0.702 -0.705 -0.734 -0.484
totalOtherIncomeExpensesNet 1M 354 000 2M -780 000 561 000 -2M 692 000 -4M 664 000 -2M
incomeBeforeTax -2M -1M -1M -2M -863 000 -6M 12M -15M -11M -11M
incomeBeforeTaxRatio -0.371 -0.17 -0.153 -0.266 -0.101 -0.727 -0.616 -0.943 -0.693 -0.582
incomeTaxExpense 0 287 000 0 889 000 2M 941 000 -45M -458 000 -664 000 2M
netIncome -3M -2M -13M -3M -3M -7M 57M -15M -11M -12M
netIncomeRatio -0.436 -0.209 -1.778 -0.376 -0.358 -0.848 -2.921 -0.914 -0.652 -0.68
eps -0.05 -0.029 -0.26 -0.059 -0.061 -0.13 0.25 -0.3 -0.22 -0.26
epsdiluted -0.05 -0.029 -0.26 -0.059 -0.061 -0.13 1.18 -0.3 -0.22 -0.26
weightedAverageShsOut 52M 52M 52M 51M 50M 50M 49M 49M 49M 49M
weightedAverageShsOutDil 52M 52M 52M 51M 50M 50M 49M 49M 49M 49M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q1 2024 q4 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-04-30 2025-01-31 2024-07-31 2024-04-30 2024-01-31 2023-10-31 2023-07-31 2023-04-30 2023-01-31 2022-10-31
symbol ENZ ENZ ENZ ENZ ENZ ENZ ENZ ENZ ENZ ENZ
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 316 253 316 253 316 253 316 253 316 253 316 253 316 253 316 253 316 253 316 253
fillingDate 2025-06-16 2025-03-17 2024-10-29 2024-06-13 2024-03-13 2023-12-15 2023-11-03 2023-06-14 2023-03-20 2022-12-12
acceptedDate 2025-06-16 17:08:51 2025-03-17 16:15:19 2024-10-29 17:04:55 2024-06-13 16:15:33 2024-03-13 16:25:22 2023-12-15 16:15:29 2023-11-03 17:07:13 2023-06-14 17:14:22 2023-03-20 17:17:09 2022-12-12 17:02:46
calendarYear 2025 2025 2024 2024 2024 2024 2023 2023 2023 2023
period Q3 Q2 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
cashAndCashEquivalents 37M 40M 52M 62M 65M 69M 82M 3M 5M 12M
shortTermInvestments 0 0 5M 0 0 0 0 0 0 0
cashAndShortTermInvestments 37M 40M 57M 62M 65M 69M 82M 3M 5M 12M
netReceivables 4M 4M 4M 4M 5M 4M 5M 10M 11M 12M
inventory 6M 6M 7M 7M 8M 8M 8M 15M 16M 16M
otherCurrentAssets 2M 2M 2M 7M 3M 2M 2M 4M 5M 5M
totalCurrentAssets 48M 52M 70M 76M 81M 88M 98M 32M 36M 45M
propertyPlantEquipmentNet 15M 15M 15M 16M 16M 16M 17M 31M 31M 32M
goodwill 0 0 0 0 0 0 0 7M 7M 7M
intangibleAssets 0 0 0 0 0 0 0 0 0 0
goodwillAndIntangibleAssets 0 0 0 0 0 0 0 7M 7M 7M
longTermInvestments 0 0 0 0 0 0 0 0 0 0
taxAssets 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 386 000 427 000 530 000 2M 2M 2M 7M 2M 2M 2M
totalNonCurrentAssets 15M 15M 16M 18M 18M 18M 23M 40M 40M 41M
otherAssets 0 0 0 1 1 0 0 0 0 0
totalAssets 64M 68M 86M 93M 99M 106M 122M 72M 76M 85M
accountPayables 1M 672 000 1M 2M 1M 2M 4M 14M 13M 8M
shortTermDebt 954 000 817 000 917 000 4M 4M 4M 4M 11M 7M 4M
taxPayables 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 0 10M 12M 17M 0 0
otherCurrentLiabilities 15M 16M 23M 16M 20M 13M 21M 75 000 12M 13M
totalCurrentLiabilities 17M 17M 25M 22M 25M 29M 40M 42M 32M 24M
longTermDebt 2M 2M 3M 3M 234 000 3M 3M 11M 11M 16M
deferredRevenueNonCurrent 0 0 0 0 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 0 0 0 0 0 0 0 0 0 0
otherNonCurrentLiabilities 1M 2M 2M 0 3M 0 0 0 0 0
totalNonCurrentLiabilities 3M 4M 5M 3M 3M 3M 3M 11M 11M 16M
otherLiabilities 0 0 0 1 1 0 0 0 0 0
capitalLeaseObligations 3M 0 3M 3M 3M 4M 4M 14M 15M 16M
totalLiabilities 20M 21M 30M 24M 28M 32M 43M 53M 44M 40M
preferredStock 0 0 0 0 0 0 0 0 0 0
commonStock 523 000 523 000 521 000 511 000 504 000 504 000 499 000 496 000 487 000 487 000
retainedEarnings -302M -299M -294M -281M -278M -275M -268M -326M -311M -299M
accumulatedOtherComprehensiveIncomeLoss 2M 2M 2M 2M 2M 3M 2M 2M 3M 4M
othertotalStockholdersEquity 343M 343M 348M 347M 346M 346M 344M 342M 340M 340M
totalStockholdersEquity 43M 47M 56M 69M 71M 74M 78M 19M 33M 45M
totalEquity 43M 47M 56M 69M 71M 74M 78M 19M 33M 45M
totalLiabilitiesAndStockholdersEquity 64M 68M 86M 93M 99M 106M 122M 72M 76M 85M
minorityInterest 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 64M 68M 86M 93M 99M 106M 122M 72M 76M 85M
totalInvestments 0 0 5M 0 0 0 0 0 0 0
totalDebt 3M 3M 4M 7M 7M 7M 7M 22M 19M 19M
netDebt -34M -37M -49M -55M -58M -62M -75M 19M 14M 7M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q1 2024 q4 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-04-30 2025-01-31 2024-07-31 2024-04-30 2024-01-31 2023-10-31 2023-07-31 2023-04-30 2023-01-31 2022-10-31
symbol ENZ ENZ ENZ ENZ ENZ ENZ ENZ ENZ ENZ ENZ
reportedCurrency USD USD USD USD USD USD USD USD USD USD
cik 316 253 316 253 316 253 316 253 316 253 316 253 316 253 316 253 316 253 316 253
fillingDate 2025-06-16 2025-03-17 2024-10-29 2024-06-13 2024-03-13 2023-12-15 2023-11-03 2023-06-14 2023-03-20 2022-12-12
acceptedDate 2025-06-16 17:08:51 2025-03-17 16:15:19 2024-10-29 17:04:55 2024-06-13 16:15:33 2024-03-13 16:25:22 2023-12-15 16:15:29 2023-11-03 17:07:13 2023-06-14 17:14:22 2023-03-20 17:17:09 2022-12-12 17:02:46
calendarYear 2025 2025 2024 2024 2024 2024 2023 2023 2023 2023
period Q3 Q2 Q4 Q3 Q2 Q1 Q4 Q3 Q2 Q1
netIncome -3M -2M -13M -2M -863 000 -7M 57M -15M -11M -11M
depreciationAndAmortization 318 000 318 000 398 000 337 000 267 000 270 000 606 000 648 000 626 000 802 000
deferredIncomeTax 0 0 0 0 -4M 970 000 0 0 0 0
stockBasedCompensation -39 000 178 000 259 000 339 000 514 000 1M 868 000 939 000 713 000 628 000
changeInWorkingCapital -186 000 6M 8M -1M -6M -10M 5M 9M 5M -271 000
accountsReceivables 177 000 -537 000 2000 1M -767 000 2M 3M 1M 664 000 -11 000
inventory 504 000 283 000 454 000 444 000 -236 000 428 000 -425 000 401 000 83 000 -393 000
accountsPayables 881 000 -618 000 -83 000 -557 000 -1M -6M -4M 450 000 5M -407 000
otherWorkingCapital -2M 7M 8M -3M -3M 3M 6M 7M -559 000 540 000
otherNonCashItems -523 000 -7M 3M -78 000 448 000 328 000 -81M -374 000 -1M 783 000
netCashProvidedByOperatingActivities -3M -2M -1M -3M -9M -13M -17M -5M -6M -9M
investmentsInPropertyPlantAndEquipment -386 000 -70 000 -123 000 -143 000 -25 000 -254 000 -573 000 -666 000 -869 000 -652 000
acquisitionsNet 0 0 0 0 0 0 0 0 0 0
purchasesOfInvestments 0 0 0 0 0 0 0 0 0 0
salesMaturitiesOfInvestments 0 0 0 0 0 0 0 0 0 0
otherInvestingActivites 0 0 0 -143 000 0 0 102M 0 0 0
netCashUsedForInvestingActivites -386 000 -70 000 -123 000 -143 000 -25 000 -254 000 101M -666 000 -869 000 -652 000
debtRepayment -42 000 0 -4M -37 000 -22 000 -51 000 -21M -4M -62 000 -95 000
commonStockIssued 0 0 0 0 0 0 386 000 0 0 0
commonStockRepurchased 0 0 0 -7000 0 -467 000 0 0 0 0
dividendsPaid -5M -5M 0 0 0 0 0 0 0 0
otherFinancingActivites 5M 0 0 -7000 0 -467 000 16M 8M 0 0
netCashUsedProvidedByFinancingActivities -42 000 -5M -4M -44 000 -22 000 -518 000 -4M 3M -62 000 -95 000
effectOfForexChangesOnCash 44 000 -18 000 32 000 -36 000 19 000 -20 000 -155 000 26 000 48 000 -28 000
netChangeInCash -4M -7M -5M -3M -9M -14M 80M -2M -7M -9M
cashAtEndOfPeriod 37M 40M 52M 62M 65M 69M 83M 4M 6M 13M
cashAtBeginningOfPeriod 40M 48M 57M 65M 74M 83M 4M 6M 13M 23M
operatingCashFlow -3M -2M -1M -3M -9M -13M -17M -5M -6M -9M
capitalExpenditure -386 000 -70 000 -123 000 -143 000 -25 000 -254 000 -573 000 -666 000 -869 000 -652 000
freeCashFlow -4M -2M -1M -3M -9M -14M -18M -6M -7M -9M
link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link

Earning call transcript

2022 q3
2022-12-13 ET (fiscal 2023 q1)
2022 q1
2022-06-10 ET (fiscal 2022 q3)
2021 q4
2022-03-14 ET (fiscal 2022 q2)
2021 q3
2021-12-15 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 6
2025-06-30 20:30 ET
Enzo Biochem published news for 2025 q1
SEC form 6
2025-06-30 20:30 ET
Enzo Biochem published news for 2025 q1
SEC form 8
2025-06-24 11:15 ET
Enzo Biochem published news for 2025 q1
SEC form 8
2025-06-24 11:15 ET
Enzo Biochem published news for 2025 q1
SEC form 8
2025-06-24 11:15 ET
Enzo Biochem published news for 2025 q1
SEC form 8
2025-06-24 11:15 ET
Enzo Biochem published news for 2025 q1
SEC form 8
2025-06-24 11:15 ET
Enzo Biochem published news for 2025 q1
SEC form 10
2025-06-16 21:08 ET
Enzo Biochem reported for 2025 q1
SEC form 8
2025-04-22 12:42 ET
Enzo Biochem published news for 2025 q1
SEC form 8
2025-04-22 12:42 ET
Enzo Biochem published news for 2025 q1
SEC form 8
2025-03-18 00:00 ET
Enzo Biochem published news for 2024 q4
SEC form 8
2025-03-18 00:00 ET
Enzo Biochem published news for 2024 q4
SEC form 10
2025-03-17 20:15 ET
Enzo Biochem reported for 2024 q4
SEC form 10
2025-03-17 00:00 ET
Enzo Biochem reported for 2024 q4
SEC form 10
2024-12-16 16:15 ET
Enzo Biochem reported for 2024 q3
SEC form 10
2024-12-16 00:00 ET
Enzo Biochem reported for 2024 q3
SEC form 8
2024-10-29 20:02 ET
Enzo Biochem published news for 2024 q3
SEC form 8
2024-10-29 20:02 ET
Enzo Biochem published news for 2024 q3
SEC form 10
2024-10-29 17:04 ET
Enzo Biochem reported for 2024 q2
SEC form 10
2024-10-29 00:00 ET
Enzo Biochem reported for 2024 q2
SEC form 10
2024-06-13 16:15 ET
Enzo Biochem reported for 2024 q1
SEC form 10
2024-06-13 00:00 ET
Enzo Biochem reported for 2024 q1
SEC form 8
2024-03-13 16:31 ET
Enzo Biochem published news for 2023 q4
SEC form 8
2024-03-13 16:31 ET
Enzo Biochem published news for 2023 q4
SEC form 10
2024-03-13 16:25 ET
Enzo Biochem reported for 2023 q4
SEC form 10
2024-03-13 00:00 ET
Enzo Biochem reported for 2023 q4
SEC form 10
2023-12-15 16:15 ET
Enzo Biochem reported for 2023 q3
SEC form 10
2023-12-15 00:00 ET
Enzo Biochem reported for 2023 q3
SEC form 10
2023-11-03 17:07 ET
Enzo Biochem reported for 2023 q2
SEC form 10
2023-11-03 00:00 ET
Enzo Biochem reported for 2023 q2
SEC form 6
2023-09-06 18:12 ET
Enzo Biochem published news for 2023 q2
SEC form 6
2023-07-28 17:19 ET
Enzo Biochem published news for 2023 q2
SEC form 6
2023-07-24 16:32 ET
Enzo Biochem published news for 2023 q2
SEC form 10
2023-06-14 17:14 ET
Enzo Biochem reported for 2023 q1
SEC form 10
2023-06-14 00:00 ET
Enzo Biochem reported for 2023 q1
SEC form 6
2023-06-09 16:05 ET
Enzo Biochem published news for 2023 q1
SEC form 6
2023-05-30 16:15 ET
Enzo Biochem published news for 2023 q1
SEC form 6
2023-05-22 16:05 ET
Enzo Biochem published news for 2023 q1
SEC form 6
2023-05-22 06:32 ET
Enzo Biochem published news for 2023 q1
SEC form 6
2023-05-08 06:30 ET
Enzo Biochem published news for 2023 q1
SEC form 6
2023-04-13 17:24 ET
Enzo Biochem published news for 2023 q1
SEC form 6
2023-04-12 20:49 ET
Enzo Biochem published news for 2023 q1
SEC form 6
2023-04-05 16:15 ET
Enzo Biochem published news for 2023 q1
SEC form 10
2023-03-20 17:17 ET
Enzo Biochem reported for 2022 q4
SEC form 10
2023-03-20 00:00 ET
Enzo Biochem reported for 2022 q4
SEC form 6
2023-03-16 16:53 ET
Enzo Biochem published news for 2022 q4
SEC form 6
2023-03-14 16:55 ET
Enzo Biochem published news for 2022 q4
SEC form 6
2023-02-03 16:01 ET
Enzo Biochem published news for 2022 q4
SEC form 6
2022-12-20 18:10 ET
Enzo Biochem published news for 2022 q3
SEC form 10
2022-12-12 17:02 ET
Enzo Biochem reported for 2022 q3
SEC form 10
2022-12-12 00:00 ET
Enzo Biochem reported for 2022 q3
SEC form 6
2022-11-25 16:59 ET
Enzo Biochem published news for 2022 q3
SEC form 6
2022-11-03 19:29 ET
Enzo Biochem published news for 2022 q3
SEC form 6
2022-10-20 08:00 ET
Enzo Biochem published news for 2022 q3
SEC form 10
2022-10-14 16:31 ET
Enzo Biochem published news for 2022 q2
SEC form 10
2022-10-14 00:00 ET
Enzo Biochem reported for 2022 q2
SEC form 6
2022-06-24 16:15 ET
Enzo Biochem published news for 2022 q1
SEC form 10
2022-06-09 16:35 ET
Enzo Biochem published news for 2022 q1
SEC form 10
2022-06-09 00:00 ET
Enzo Biochem reported for 2022 q1
SEC form 6
2022-05-06 16:47 ET
Enzo Biochem published news for 2022 q1
SEC form 6
2022-04-27 17:29 ET
Enzo Biochem published news for 2022 q1
SEC form 6
2022-04-08 15:55 ET
Enzo Biochem published news for 2022 q1
SEC form 6
2022-03-31 17:42 ET
Enzo Biochem published news for 2021 q4
SEC form 6
2022-03-30 16:10 ET
Enzo Biochem published news for 2021 q4
SEC form 6
2022-03-18 16:23 ET
Enzo Biochem published news for 2021 q4
SEC form 10
2022-03-14 17:01 ET
Enzo Biochem published news for 2021 q4
SEC form 10
2022-03-14 00:00 ET
Enzo Biochem published news for 2021 q4
SEC form 6
2022-03-07 16:15 ET
Enzo Biochem published news for 2021 q4
SEC form 6
2022-02-28 17:32 ET
Enzo Biochem published news for 2021 q4
SEC form 6
2022-01-21 16:10 ET
Enzo Biochem published news for 2021 q4
SEC form 6
2022-01-06 17:15 ET
Enzo Biochem published news for 2021 q4
SEC form 6
2022-01-04 06:30 ET
Enzo Biochem published news for 2021 q4
SEC form 10
2021-12-15 16:10 ET
Enzo Biochem published news for 2021 q3
SEC form 10
2021-12-15 00:00 ET
Enzo Biochem published news for 2021 q3
SEC form 6
2021-12-01 12:24 ET
Enzo Biochem published news for 2021 q3
SEC form 6
2021-11-29 17:26 ET
Enzo Biochem published news for 2021 q3
SEC form 6
2021-10-18 08:18 ET
Enzo Biochem published news for 2021 q3
SEC form 10
2021-10-12 13:09 ET
Enzo Biochem published news for 2021 q2
SEC form 10
2021-10-12 00:00 ET
Enzo Biochem published news for 2021 q2
SEC form 6
2021-06-25 16:16 ET
Enzo Biochem published news for 2021 q1
SEC form 6
2021-06-14 16:10 ET
Enzo Biochem published news for 2021 q1
SEC form 10
2021-06-11 16:31 ET
Enzo Biochem published news for 2021 q1
SEC form 6
2021-06-11 11:17 ET
Enzo Biochem published news for 2021 q1
SEC form 10
2021-06-11 00:00 ET
Enzo Biochem published news for 2021 q1
SEC form 6
2021-03-19 16:41 ET
Enzo Biochem published news for 2020 q4
SEC form 10
2021-03-16 17:00 ET
Enzo Biochem published news for 2020 q4
SEC form 6
2021-03-16 16:11 ET
Enzo Biochem published news for 2020 q4
SEC form 6
2021-01-08 16:36 ET
Enzo Biochem published news for 2020 q4
SEC form 6
2021-01-06 16:00 ET
Enzo Biochem published news for 2020 q4
SEC form 6
2020-12-17 12:43 ET
Enzo Biochem published news for 2020 q3
SEC form 6
2020-12-14 16:55 ET
Enzo Biochem published news for 2020 q3
SEC form 10
2020-12-11 16:49 ET
Enzo Biochem published news for 2020 q3
SEC form 6
2020-11-27 15:30 ET
Enzo Biochem published news for 2020 q3
SEC form 6
2020-11-25 17:00 ET
Enzo Biochem published news for 2020 q3
SEC form 6
2020-11-23 17:00 ET
Enzo Biochem published news for 2020 q3
SEC form 6
2020-11-16 17:03 ET
Enzo Biochem published news for 2020 q3
SEC form 10
2020-10-19 16:54 ET
Enzo Biochem published news for 2020 q2